BridgeBio Pharma BBIO License and services revenue — Revenue

Other product segments

Similar metrics at other companies

UAALicense revenues — Revenue

$26.85M+10.9%

VERXLicense And Service — Revenue

$167.15M+10.9%

RGNXLicense And Service — Revenue

$103.84M+462%

MNKDLicense And Service — Revenue

$35.02M+53.3%

ACRSLicense And Service — Revenue

$1.27M-4.6%

KOPNLicense And Other Revenues — Revenue

$64.93K-9.7%

FAQ

What is BridgeBio Pharma's license and services revenue — revenue?

BridgeBio Pharma (BBIO) reported license and services revenue — revenue of $4.42M in Q1 2026.

How has BridgeBio Pharma's license and services revenue — revenue changed year-over-year?

BridgeBio Pharma's license and services revenue — revenue decreased by 94.5% year-over-year, from $79.69M to $4.42M.

What is the long-term trend for BridgeBio Pharma's license and services revenue — revenue?

Over 3 years (2021 to 2025), BridgeBio Pharma's license and services revenue — revenue has grown at a 22.7% compound annual growth rate (CAGR), from $65.92M to $121.88M.

What does license and services revenue — revenue mean?

This metric represents the total revenue generated from licensing intellectual property and providing related services within a specific business segment. It captures the inflow of economic benefits from partnerships, milestone achievements, and service agreements associated with the company's drug development pipeline.